JP2007517833A5 - - Google Patents

Download PDF

Info

Publication number
JP2007517833A5
JP2007517833A5 JP2006548308A JP2006548308A JP2007517833A5 JP 2007517833 A5 JP2007517833 A5 JP 2007517833A5 JP 2006548308 A JP2006548308 A JP 2006548308A JP 2006548308 A JP2006548308 A JP 2006548308A JP 2007517833 A5 JP2007517833 A5 JP 2007517833A5
Authority
JP
Japan
Prior art keywords
disease
preparation according
illness
formulation
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006548308A
Other languages
English (en)
Japanese (ja)
Other versions
JP5052138B2 (ja
JP2007517833A (ja
Filing date
Publication date
Priority claimed from PL04364348A external-priority patent/PL364348A1/xx
Application filed filed Critical
Publication of JP2007517833A publication Critical patent/JP2007517833A/ja
Publication of JP2007517833A5 publication Critical patent/JP2007517833A5/ja
Application granted granted Critical
Publication of JP5052138B2 publication Critical patent/JP5052138B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006548308A 2004-01-12 2005-01-07 四級ピリジニウム塩の血管保護剤としての使用 Expired - Lifetime JP5052138B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL04364348A PL364348A1 (en) 2004-01-12 2004-01-12 Application of quaternary pyridine salts as vessel protection agent
PLP-364348 2004-01-12
PCT/EP2005/050057 WO2005067927A2 (en) 2004-01-12 2005-01-07 The use of quaternary pyridinium salts as vasoprotective agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011233155A Division JP5597179B2 (ja) 2004-01-12 2011-10-24 四級ピリジニウム塩の血管保護剤としての使用

Publications (3)

Publication Number Publication Date
JP2007517833A JP2007517833A (ja) 2007-07-05
JP2007517833A5 true JP2007517833A5 (https=) 2008-01-17
JP5052138B2 JP5052138B2 (ja) 2012-10-17

Family

ID=34793495

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006548308A Expired - Lifetime JP5052138B2 (ja) 2004-01-12 2005-01-07 四級ピリジニウム塩の血管保護剤としての使用
JP2011233155A Expired - Lifetime JP5597179B2 (ja) 2004-01-12 2011-10-24 四級ピリジニウム塩の血管保護剤としての使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011233155A Expired - Lifetime JP5597179B2 (ja) 2004-01-12 2011-10-24 四級ピリジニウム塩の血管保護剤としての使用

Country Status (13)

Country Link
US (6) US7935717B2 (https=)
EP (2) EP2279738A1 (https=)
JP (2) JP5052138B2 (https=)
CN (1) CN1905875B (https=)
AT (1) ATE524179T1 (https=)
AU (1) AU2005205066C1 (https=)
CA (1) CA2547234C (https=)
DK (1) DK1713480T3 (https=)
ES (1) ES2372756T3 (https=)
PL (2) PL364348A1 (https=)
PT (1) PT1713480E (https=)
RU (1) RU2366420C2 (https=)
WO (1) WO2005067927A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL364348A1 (en) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
AU2006329564A1 (en) 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
EP1963270B1 (en) * 2005-12-09 2009-08-05 Cerecon AG Quaternary 3 -amido, n-methylpyridinium salts as anti -inflammatory agents
PT2026651E (pt) 2006-03-08 2013-06-04 Cortria Corp Terapia combinada com inibidores cox não selectivos para prevenir lesões gástricas relacionadas com a cox
JP2010506900A (ja) * 2006-10-18 2010-03-04 デルメナ リポ蛋白質異常症並びに皮膚疾病および皮膚障害の処置のためのｎ−メチルニコチンアミドを含有する食品抽出物
PL381862A1 (pl) * 2007-02-28 2008-09-01 Trigendo Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie związków pirydyniowych i sposób leczenia
US20090118225A1 (en) * 2007-09-28 2009-05-07 Cortria Corporation 1-Methyl Nicotinamide and Derivatives for Treatment of Gastric Injury
EP2211857B1 (en) * 2007-10-12 2012-09-12 Politechnika Lodzka Use of quaternary pyridinium salts for radioprotection
US8304439B1 (en) 2007-10-12 2012-11-06 Politechnika Lodzka Use of quaternary pyridinium salts as a therapeutic or preventing agent against ionizing radiation-induced damage
PL2211858T3 (pl) 2007-10-12 2015-06-30 Politechnika Lodzka Zastosowanie czwartorzędowych soli pirydyniowych do hamowania przerzutów nowotworowych
EP2285379A4 (en) * 2008-05-06 2011-11-02 Cortria Corp ANALOGUES OF 1-METHYLNICOTINAMIDE
CA2764739A1 (en) * 2008-07-01 2010-01-07 Politechnika Lodzka N'-nitroxyalkylnicotinamides for the treatment of cardiovascular diseases
US8575175B2 (en) 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
EP2186419A1 (en) * 2008-11-13 2010-05-19 Tchibo GmbH NMP-containing extract, a method of its production and uses thereof
RU2425672C1 (ru) * 2010-04-12 2011-08-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипергомоцистеин-индуцированной эндотелиальной дисфункции смесью растворов гомеопатических разведений поликлональных кроличьих антител к эндотелиальной синтазе оксида азота человека - с12, с30, с200
KR101309576B1 (ko) * 2011-05-25 2013-09-17 연세대학교 산학협력단 대사물질을 이용한 심부전 바이오마커
PL226999B1 (pl) * 2013-06-11 2017-10-31 Univ Jagiellonski Azotan (III) 3 -karbamoilo -1-metylopirydyniowy, sposób jego otrzymywania izastosowanie
CN105771005A (zh) * 2016-03-24 2016-07-20 乐普（北京）医疗器械股份有限公司 一种抗风湿性血管狭窄药物支架及其制备方法和应用
WO2018015862A1 (en) 2016-07-18 2018-01-25 Pharmena S.A. 1-methylnicotinamide salts for use in raising the blood levels of adiponectin
DK3484475T3 (da) * 2016-07-18 2023-11-27 Pharmena S A 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom
ES2998765T3 (en) * 2017-07-27 2025-02-21 Univ Michigan Regents Plasminogen activator inhibitor-1 (pai-1) inhibitor and method of use
PL238932B1 (pl) * 2017-12-31 2021-10-18 Univ Jagiellonski Pochodne soli pirydyniowych oraz ich zastosowanie
US10864207B2 (en) * 2019-01-02 2020-12-15 Celagenex Research (India) Pvt. Ltd. Method of treating endothelial dysfunction
WO2021205341A1 (en) 2020-04-07 2021-10-14 Pharmena S.A. 1-methylnicotinamide for the prevention/treatment of inflammatory airway diseases
WO2022061234A2 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Immunological effects of metabolites
CN115837023B (zh) * 2023-02-20 2023-05-16 中山大学附属第八医院（深圳福田） 1-甲基烟酰胺在制备抗血管钙化药物中的应用
PL248942B1 (pl) * 2024-01-31 2026-02-16 Politechnika Poznanska Czwartorzędowe sole amoniowe zawierające anion 2-furanokarboksylanowy i kation będący alkilową pochodną nikotynamidu, sposób ich otrzymywania i zastosowanie jako środki myjąco-dezynfekujące
PL447656A1 (pl) * 2024-01-31 2025-08-04 Politechnika Poznańska Nowe czwartorzędowe sole amoniowe zawierające anion pochodzący od kwasu nikotynowego oraz kation N-alkilonikotynamidowy, sposób ich otrzymywania oraz zastosowanie jako substancje o aktywności przeciwbakteryjnej
PL449092A1 (pl) * 2024-07-01 2026-01-05 Uniwersytet Jagielloński Synergiczna kombinacja 1-metylonikotynamidu (MNA) i witaminy K do zastosowania w leczeniu lub zapobieganiu powikłaniom sercowo-naczyniowym terapii przeciwnowotworowych

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB675430A (en) 1949-07-12 1952-07-09 Cilag Ltd Novel quaternary nicotinic acid amide derivatives and production thereof
DE840698C (de) * 1949-07-12 1952-06-05 Cilag Aktiengesellschaft Verfahren zur herstellung neuer derivate des nicotinsaureamids
US5260305A (en) 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US20060263428A1 (en) 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6406715B1 (en) 1993-09-20 2002-06-18 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US20030157153A1 (en) 1997-03-06 2003-08-21 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US6469035B1 (en) 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
IE970731A1 (en) 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
PL190755B1 (pl) 1999-01-07 2006-01-31 Pharmena Sp Z Oo Preparat do leczenia i profilaktyki chorób skóry
JP2002255846A (ja) * 2001-02-26 2002-09-11 Sunstar Inc 経口組成物
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US20050130990A1 (en) 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US7153870B2 (en) * 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
PL364348A1 (en) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
CN101076331A (zh) 2004-11-05 2007-11-21 艾尼纳制药公司 包含烟酸受体部分促效剂的用于治疗发红和脂质相关病症的组合物
AU2006329564A1 (en) 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
JP2010506900A (ja) * 2006-10-18 2010-03-04 デルメナ リポ蛋白質異常症並びに皮膚疾病および皮膚障害の処置のためのｎ−メチルニコチンアミドを含有する食品抽出物
PL381862A1 (pl) 2007-02-28 2008-09-01 Trigendo Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie związków pirydyniowych i sposób leczenia

Similar Documents

Publication Publication Date Title
JP2007517833A5 (https=)
RU2006129299A (ru) Применение четвертичных солей пиридиния в качестве вазопротекторных средств
JP2019513126A5 (https=)
JP2016523243A5 (https=)
JP2009531292A5 (https=)
JP2017105819A5 (https=)
JP2004522714A5 (https=)
JP2010529101A (ja) 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用
RU2009135821A (ru) Применение четвертичных соединений пиридиния для вазопротекции и/или гепатопротекции
JP2017522352A5 (https=)
JP2007518769A5 (ja) 内皮前駆細胞の刺激並びに臓器の再生及び末端器官障害の進行の抑制のための低用量エリスロポエチンの使用
US6124322A (en) Intravenous form of thalidomide for treating immunological diseases
JP2014185161A (ja) シロスタゾールを含むカルボスチリル誘導体の脂肪肝治療剤
JPS61254524A (ja) 抗血栓形成性医薬組成物
Alkhawajah et al. Fatal anaphylactic reaction to diclofenac
JP2025160480A (ja) 不眠症を治療するためのレンボレキサントの使用
JPS597163A (ja) 抗動脈硬化剤
WO1995005825A1 (en) Circulatory disturbance ameliorant
US5530001A (en) Pharmaceutical use of dihydropyridine derivative
JP2020520904A5 (https=)
JP2532918B2 (ja) グアニジノ安息香酸誘導体を有効成分として含有する抗動脈硬化剤
CN103830237B (zh) 一种伊拉地平组合药物、胶囊剂、制备方法及其应用
JPWO2021231208A5 (https=)
JP2013147515A (ja) 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用
CN119613310A (zh) 一种伊洛前列素衍生物及其制备方法和应用